DNA patents and scientific discovery and innovation: Assessing benefits and risks

[1]  D. Normile.  Monsanto Donates Its Share of Golden Rice , 2000, Science.

[2]  R. Dreyfuss.  Collaborative Research: Conflicts on Authorship, Ownership, and Accountability , 2000 .

[3]  E. Pennisi.  Stealth Genome Rocks Rice Researchers , 2000, Science.

[4]  E Marshall,et al.  A Deluge of Patents Creates Legal Hassles for Research , 2000, Science.

[5]  Stephen M. Mount,et al.  The genome sequence of Drosophila melanogaster. , 2000, Science.

[6]  L Roberts,et al.  SNP Mappers Confront Reality and Find It Daunting , 2000, Science.

[7]  E. Marshall.  Talks of Public-Private Deal End in Acrimony , 2000, Science.

[8]  E Marshall,et al.  Patent on HIV Receptor Provokes an Outcry , 2000, Science.

[9]  M. Enserink.  Patent Office May Raise the Bar on Gene Claims , 2000, Science.

[10]  T. Reynolds.  Gene patent race speeds ahead amid controversy, concern. , 2000, Journal of the National Cancer Institute.

[11]  T. Paul,et al.  The "EST" Dilemma: Should the Discovery of a Part of a Gene Lead to a Patent That Could Cover the Entire Gene Once Discovered? , 1999 .

[12]  M. Barinaga.  Genentech, UC Settle Suit for $200 Million , 1999, Science.

[13]  M. Friedberg,et al.  Evaluation of conflict of interest in economic analyses of new drugs used in oncology. , 1999, JAMA.

[14]  E. Marshall.  A High-Stakes Gamble on Genome Sequencing , 1999, Science.

[15]  M. Wadman.  NIH strives to keep resource sharing alive , 1999, Nature.

[16]  B. Knoppers.  Status, sale and patenting of human genetic material: an international survey , 1999, Nature Genetics.

[17]  E. Marshall.  Drug Firms to Create Public Database of Genetic Mutations , 1999, Science.

[18]  S. Nadis.  US concern grows over secrecy clauses , 1999, Nature.

[19]  Noel C. Harris.  It's time to ‘out’ the selfish researchers , 1999, Nature.

[20]  Thomas.  Genomics and intellectual property rights. , 1999, Drug discovery today.

[21]  Dick Thompson,et al.  Racing to map our DNA. , 1999, Time.

[22]  D. Resnik.  Conflicts of Interest in Science , 1998, Perspectives on Science.

[23]  D S Block,et al.  Patenting Genomic Technologies , 1998, Science.

[24]  J. L. Tribble.  Gene Patents—A Pharmaceutical Perspective , 1998, Cambridge Quarterly of Healthcare Ethics.

[25]  G. Mcgee.  Gene Patents Can Be Ethical , 1998, Cambridge Quarterly of Healthcare Ethics.

[26]  M. Cho,et al.  Disease Genes Are Not Patentable: A Rebuttal of McGee , 1998, Cambridge Quarterly of Healthcare Ethics.

[27]  E. Vesell,et al.  Genetic Variation as a Guide to Drug Development , 1998, Science.

[28]  D. Nelkin,et al.  Homo economicus: commercialization of body tissue in the age of biotechnology. , 1998, The Hastings Center report.

[29]  J. Enríquez.  Genomics and the World's Economy , 1998, Science.

[30]  D. Resnik.  Industry‐Sponsored Research: Secrecy versus Corporate Responsibility , 1998 .

[31]  D. Resnik.  The ethics of science , 1998 .

[32]  M. Heller,et al.  Can Patents Deter Innovation? The Anticommons in Biomedical Research , 1998, Science.

[33]  J J Doll,et al.  The Patenting of DNA , 1998, Science.

[34]  Leonard,et al.  Disease Gene Patenting Is a Bad Innovation. , 1997, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

[35]  M. Hanson.  Religious voices in biotechnology: the case of gene patenting. , 1997, The Genetic resource.

[36]  M. Hanson.  Religious voices in biotechnology: the case of gene patenting. , 1997, The Hastings Center report.

[37]  Melissa S. Anderson,et al.  Withholding research results in academic life science. Evidence from a national survey of faculty. , 1997, JAMA.

[38]  D. Resnik.  The Morality of Human Gene Patents , 1997, Kennedy Institute of Ethics journal.

[39]  Frederick H. Buttel,et al.  University-Business Partnerships: An Assessment. , 1997 .

[40]  Rebecca S. Eisenberg,et al.  Structure and function in gene patenting , 1997, Nature Genetics.

[41]  A. Jaffe.  Trends and patterns in research and development expenditures in the United States. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[42]  W. Gibbs.  The Price of Silence , 1996 .

[43]  P. Kahn.  Coming to Grips With Genes and Risk , 1996, Science.

[44]  C. Munthe,et al.  The morality of scientific openness , 1996, Science and engineering ethics.

[45]  L S Rothenberg,et al.  Financial interests of authors in scientific journals: A pilot study of 14 publications , 1996, Science and engineering ethics.

[46]  L. Guenin.  Norms for patents concerning human and other life forms , 1996, Theoretical medicine.

[47]  M. Svatos.  Biotechnology and the Utilitarian Argument for Patents , 1996, Social Philosophy and Policy.

[48]  W. M. Carson,et al.  Drugs by design. , 1993, Scientific American.

[49]  Henry E. Kyburg,et al.  Science as Process. , 1993 .

[50]  J. Andre,et al.  Blocked Exchanges: A Taxonomy , 1992, Ethics.

[51]  D. Kevles,et al.  Plants as Intellectual Property: American Practice, Law, and Policy in World Context , 1992, Osiris.

[52]  David L. Hull,et al.  Science as a Process: An Evolutionary Account of the Social and Conceptual Development of Science, David L. Hull. 1988. The University of Chicago Press, Chicago, IL. 608 pages. ISBN: 0-226-35060-4. $39.95 , 1989 .

[53]  R. Davidson.  Source of funding and outcome of clinical trials , 1986, Journal of general internal medicine.

[54]  J. Ravetz.  Sociology of Science , 1972, Nature.

[55]  Jeremy Rifkin,et al.  The Biotech Century , 1998 .

[56]  T. Beardsley.  Trends in biological research. Big-time biology. , 1994, Scientific American.

[57]  A. Kantorovich.  Scientific discovery , 1993 .

[58]  Merrilee H. Salmon.  Introduction to the Philosophy of Science , 1992 .